Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

61.96
+1.532.53%
Post-market: 62.500.5400+0.87%19:13 EDT
Volume:577.76K
Turnover:35.52M
Market Cap:1.77B
PE:158.87
High:62.91
Open:61.15
Low:59.59
Close:60.43
52wk High:66.37
52wk Low:14.27
Shares:28.58M
Float Shares:26.78M
Volume Ratio:1.03
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):-0.1710
ROE:35.97%
ROA:11.86%
PB:38.02
PE(LYR):-362.36

Loading ...

GUIDANCE: (ETON) Eton Pharmaceuticals Expects Full Year 2026 Revenue Over $145M, vs. FactSet Est of $121.3M

MT Newswires Live
·
Aug 14

Eton Pharmaceuticals Q2 Net Income USD 11.578 Million

Reuters
·
Aug 14

Eton Pharmaceuticals Inc: ‍Company NOW Expects 2026 Revenues to Exceed $145 Mln​

THOMSON REUTERS
·
Aug 14

Eton Pharmaceuticals Inc: ‍ Company NOW Expects to Report at Least a 35% Adjusted Ebitda Margin in 2026​

THOMSON REUTERS
·
Aug 14

Eton Pharmaceuticals Q2 EPS USD 0.35

THOMSON REUTERS
·
Aug 14

U.S. Earnings Preview: After Market Close Aug. 13

Dow Jones
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)

TIPRANKS
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Simply Wall St.
·
Aug 13

Eton Pharma COO Danka Radosavljevic Files Initial Beneficial Ownership Statement

Reuters
·
Aug 13

Eton Pharmaceuticals Inc Expected to Post Earnings of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Eton Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $65 from $57

THOMSON REUTERS
·
Aug 11

Earning Preview: Eton Pharmaceuticals, Inc. Q2 revenue is expected to increase by 62.24%, and institutional views are bullish

Earnings Agent
·
Aug 06

Eton Pharmaceuticals Plans ASN-001 NDA Submission in 2H 2027 After Infantile Hemangioma Phase Ii/iii Data

Reuters
·
Aug 05

Eton Pharmaceuticals Licenses US Rights to Auson’s ASN-001 for Infantile Hemangiomas

Reuters
·
Aug 05

Eton Pharmaceuticals - Anticipates Nda Submission for Asn-001 in 2H 2027, Potential Launch in 2028

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate Asn-001

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Names Danka Radosavljevic Chief Operating Officer

Reuters
·
Aug 04

Eton Pharma to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Aug 03

Is Eton Pharmaceuticals (ETON) Quietly Reframing Its Orphan-Drug Strategy With KHINDIVI’s Label Expansion Bid?

Simply Wall St.
·
Jul 30